How has ArriVent BioPharma, Inc.'s operating lease liabilities changed year-over-year?

ArriVent BioPharma, Inc.'s operating lease liabilities increased by 1275.0% year-over-year, from -$4K to $47K.

ArriVent BioPharma, Inc. AVBP Operating lease liabilities

Operating lease liabilities at other companies

ImmunomeIMNM

——

Bicara TherapeuticsBCAX

——

BridgeBio PharmaBBIO

——

Revolution Medicines, Inc.RVMD

——

Roivant SciencesROIV

——

Natera, Inc.NTRA

——

Other financials

Income statement

See full

Operating income-$46.1M+30.9%

Net income-$43.3M+32.7%

EPS (diluted)-$0.96+49.5%

Balance sheet

See full

Cash & equivalents$62.1M+24.5%

Total debt$419.0K+204%

Total equity$324.0M+60.0%

Total assets$349.3M+62.1%

Cash flow

See full

Operating cash flow-$41.9M+38.4%

Valuation

See full

Market cap$1.57B+62.1%

Enterprise value$1.51B+65.4%

Returns & leverage

See full

Return on equity-55.2%+8.0pp

Debt / equity0×0.0×

Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s operating lease liabilities?: ArriVent BioPharma, Inc. (AVBP) reported operating lease liabilities of $47K in Q1 2026.
How has ArriVent BioPharma, Inc.'s operating lease liabilities changed year-over-year?: ArriVent BioPharma, Inc.'s operating lease liabilities increased by 1275.0% year-over-year, from -$4K to $47K.